Pembrolizumab receives the green light from NICE for NSCLC subtype

Written by Jade Parker, Senior Editor

Pembrolizumab (Keytruda®) is to be made available as a treatment option, in combination with chemotherapy, for the first-line treatment of adults with untreated metastatic squamous non-small cell lung cancer (NSCLC) via the Cancer Drugs Fund following a recommendation from NICE. The decision to recommend pembrolizumab makes it the first immunotherapy to be used in the first-line setting for metastatic squamous NSCLC regardless of PD-L1 expression, when combined with chemotherapy. “Pembrolizumab combination therapy is a promising treatment option for these patients who currently have very few. We are therefore pleased to be able to use the flexibility provided by the Cancer...

To view this content, please register now for access

It's completely free